19,142 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Brummer Multi Strategy AB

Brummer Multi Strategy AB purchased a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 19,142 shares of the biopharmaceutical company’s stock, valued at approximately $1,175,000. PTC Therapeutics makes up 21.4% of Brummer Multi Strategy AB’s investment portfolio, making the stock its 2nd biggest holding.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Smartleaf Asset Management LLC grew its holdings in shares of PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 236 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in PTC Therapeutics by 42.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 295 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of PTC Therapeutics by 247.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 814 shares during the period. Globeflex Capital L P acquired a new position in shares of PTC Therapeutics in the second quarter valued at about $91,000. Finally, Plato Investment Management Ltd purchased a new position in shares of PTC Therapeutics in the second quarter worth about $92,000.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $76.35, for a total value of $916,200.00. Following the sale, the director directly owned 18,500 shares of the company’s stock, valued at approximately $1,412,475. This trade represents a 39.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Allan Steven Jacobson sold 14,199 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $83.55, for a total value of $1,186,326.45. Following the completion of the sale, the director owned 17,451 shares of the company’s stock, valued at $1,458,031.05. This trade represents a 44.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 298,246 shares of company stock valued at $23,393,870 in the last ninety days. 5.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on PTCT shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of PTC Therapeutics in a research report on Friday. Bank of America decreased their price objective on shares of PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research note on Friday. Barclays upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $68.00 to $119.00 in a research note on Tuesday, January 27th. Jefferies Financial Group raised their target price on shares of PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Ten analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $80.73.

PTC Therapeutics Stock Performance

Shares of NASDAQ PTCT opened at $70.66 on Friday. The company has a market capitalization of $5.67 billion, a PE ratio of 9.13 and a beta of 0.48. The company’s fifty day moving average price is $74.91 and its 200 day moving average price is $68.02. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 373.67% and a net margin of 39.44%.The firm had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. During the same quarter last year, the company posted ($0.85) EPS. The company’s revenue was down 22.7% on a year-over-year basis. On average, equities analysts expect that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.